Nightingale Health Plc – Managers’ transactions – Tuukka Paavola

Managers' Transactions, 2 October 2023 at 9:30 (EEST)  

____________________________________________  

Person subject to the notification requirement  

Name: Tuukka Paavola  

Position: Chief Financial Officer  

Issuer: Nightingale Health Oyj  

LEI: 743700WUIPC24LVMLO66  

Notification type: INITIAL NOTIFICATION  

Reference number: 39623/5/4  

____________________________________________  

Transaction date: 2023-09-29  

Venue: FIRST NORTH GROWTH MARKET FINLAND (FSME)  

Instrument type: SHARE  

ISIN: FI4000490875  

Nature of transaction: ACQUISITION  

Transaction details  

(1): Volume: 4587 Unit price: 1.034 EUR  

(2): Volume: 2900 Unit price: 1.03 EUR  

Aggregated transactions (2):  

Volume: 7487 Volume weighted average price: 1.03245 EUR  

For further information, please contact:  

Teemu Suna, CEO  
ir@nightingalehealth.com  

Certified Adviser:  
Oaklins Merasco Ltd, tel. +358 9 6129 670  

About Nightingale Health  

Nightingale Health is The Preventative Health Company. Staying healthy is one of the top priorities in human life. Our health has a profound impact on our quality of life, and it’s also strongly connected to the lives of those close to us. Nightingale Health enables prevention by combining the power of our in-house developed, advanced blood analysis technology with unprecedented access to global health repositories and world-leading medical research. With this combination, we go beyond the traditional healthcare and wellbeing tools: We provide the scientific connection to multiple health and disease outcomes and the ability to predict future healthy years.  

Nightingale Health operates globally with a parent company in Finland and seven subsidiaries in countries such as Japan, the United States, Singapore, and the United Kingdom. Nightingale Health has customers in more than 25 countries in the healthcare and medical research sectors. The company’s technology is being used in many of the world’s leading health initiatives, such as the UK Biobank, and over 450 peer-reviewed publications validate the technology. The company’s Series B shares are listed on the First North Growth Market Finland marketplace. Read more: https://nightingalehealth.com 

Tags: